Table 1.
Study | Year | Ethnicity | Tumor cases | Normal controls | Methods | Materials |
---|---|---|---|---|---|---|
Antelo et al (early onset)20 | 2012 | Non-Asian | 185 | 32 | Pyrosequencing | FFPE |
Antelo et al (Lynch syndrome)20 | 2012 | Non-Asian | 20 | 32 | Pyrosequencing | FFPE |
Antelo et al (older onset sporadic MSI)20 | 2012 | Non-Asian | 46 | 32 | Pyrosequencing | FFPE |
Antelo et al (older onset sporadic MSS)20 | 2012 | Non-Asian | 89 | 32 | Pyrosequencing | FFPE |
Matsunoki et al21 | 2012 | Asian | 48 | 48 | Multicolor MethyLight assay | FFPE |
Hur et al22 | 2014 | Non-Asian | 77 | 77 | Pyrosequencing | FFPE |
Rhee et al23 | 2012 | Asian | 207 | NA | Pyrosequencing | FFPE |
Estecio et al12 | 2007 | Non-Asian | 60 | 60 | Pyrosequencing | Fresh tissues |
Pavicic et al (sporadic MSS)24 | 2012 | Non-Asian | 55 | 55 | COBRA | FFPE |
Pavicic et al (sporadic MSI)24 | 2012 | Non-Asian | 52 | 52 | COBRA | FFPE |
Pavicic et al (Lynch syndrome)24 | 2012 | Non-Asian | 43 | 43 | COBRA | FFPE |
Pavicic et al (FCCX)24 | 2012 | Non-Asian | 18 | 18 | COBRA | FFPE |
Imamura et al25 | 2014 | Non-Asian | 1,267 | NA | Pyrosequencing | FFPE |
Morikawa et al26 | 2012 | Non-Asian | 1,060 | NA | Pyrosequencing | FFPE |
Shima et al27 | 2011 | Non-Asian | 1,072 | NA | Pyrosequencing | FFPE |
Baba et al10 | 2010 | Non-Asian | 869 | NA | Pyrosequencing | FFPE |
Hazra et al28 | 2010 | Non-Asian | 182 | NA | Pyrosequencing | FFPE |
Ogino et al29 | 2009 | Non-Asian | 647 | NA | Pyrosequencing | FFPE |
Ogino et al30 | 2009 | Non-Asian | 82 | NA | Pyrosequencing | FFPE |
Lou et al31 | 2015 | Asian | 129 | NA | Pyrosequencing | FFPE |
Yamauchi et al32 | 2012 | Non-Asian | 1188 | NA | Pyrosequencing | FFPE |
Abbreviations: COBRA, combined bisulfite restriction analysis; FCCX, familial colorectal cancer type X; FFPE, formalin fixed paraffin embedded; MSI, microsatellite instability; MSS, microsatellite stability; NA, not available.